摘要
["Background The antiviral therapy has been considered as an ordinary intervention for COVID-19 patients. However, the effectiveness of antiviral therapy is uncertain. This study was designed to determine the association between the antiviral therapy and in-hospital mortality among severe COVID-19 patients.","Methods This study enrolled severe COVID-19 patients admitted to four designated hospitals in Wuhan, China. The use of antiviral treatments, demographics, laboratory variables, co-morbidities, complications, and other treatments were compared between survival and fatal cases. The association between antiviral agents and in-hospital mortality were analyzed.","Results In total, 109 severe COVID-19 patients (mean age 65.43) were enrolled for analysis, among which, 61 (56.0%) patients were discharged alive, and 48 (44.0%) died during hospitalization. We found no association between lopinavir/ritonavir (LPV/r) treatment and the in-hospital mortality (odds ratio (OR) = 0.195, 95% confidence interval (CI) = 0.023-1.679). Besides, ribavirin (OR = 0.738, 95% CI = 0.344-1.582), oseltamivir (OR = 0.765, 95% CI = 0.349-1.636), and interferon-alpha (IFN-a) (OR = 0.371, 95% CI = 0.112-1.236) were not associated with the in-hospital mortality. However, arbidol monotherapy (OR = 5.027, 95% CI = 1.79514.074) or the combination of arbidol and oseltamivir (OR = 5.900, 95% CI =1.190-29.247) was associated with an increased in-hospital mortality. In addition, the multiple logistic regression identified a significant association between the use of arbidol and the in-hospital mortality (adjusted OR = 4.195, 95% CI = 1.221-14.408).","Conclusions Our findings indicated that LPV/r, IFN-a, ribavirin, or oseltamivir have no beneficial effects on the prognosis of severe COVID-19 patients, whereas the use of arbidol is associated with increased in-hospital mortality."]
| 源语言 | 英语 |
|---|---|
| 期刊论文编号 | 05017 |
| 页数 | 8 |
| 期刊 | Journal of Global Health |
| 卷 | 11 |
| DOI | |
| 出版状态 | 已出版 - 1月 2021 |
基金资助
This study was supported by Natural Science Foundation of Shandong Province, China (ZR2017MH100), the Academic Promotion Program of Shandong First Medical University (No. 2019RC010), the Young Taishan Scholars Program of Shandong Province of China (No. tsqn20161046), and Shandong Province Higher Educational Young and Innovation Technology Supporting Program (No. 2019KJL004).
收录
- SCIE
- SSCI
学术指纹
探究 'Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver